Whitehawk Therapeutics Presents Promising Preclinical Data for Next-Gen ADC Portfolio

Data demonstrate potential for differentiated, best-in-class therapeutic index among TOP1i-based ADCs

Apr. 19, 2026 at 10:30pm

Got story updates? Submit your updates here. ›

A minimalist design in the style of Keith Haring where the outline of a biological structure is defined entirely by glowing, vibrant neon lines against a dark background, emphasizing the internal mechanisms of a cancer treatment technology.Whitehawk's novel ADC platform aims to unlock the full potential of antibody-drug conjugates as targeted cancer therapies.San Diego Today

Whitehawk Therapeutics, a clinical-stage oncology company, presented new preclinical data across its antibody-drug conjugate (ADC) portfolio at the AACR 2026 Annual Meeting. The data demonstrate potent tumor regressions, high plasma stability, and favorable tolerability for the company's next-generation ADC candidates HWK-007, HWK-016, and HWK-206, which are built on Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform.

Why it matters

Whitehawk's preclinical data suggest its ADC portfolio has the potential to deliver a differentiated therapeutic index compared to existing TOP1i-based ADCs, which is crucial for realizing the full promise of ADCs as cancer treatments. The company's novel bioconjugation and linker-payload technologies aim to address limitations of first-generation ADCs.

The details

The preclinical data presented at AACR 2026 showed that Whitehawk's ADC candidates exhibited potent tumor cell killing, bystander activity, and tumor regressions at low single-digit mg/kg doses in various cancer models. The ADCs also demonstrated favorable pharmacokinetics and were well-tolerated in non-human primates, with low systemic levels of free payload detected in circulation.

  • Whitehawk plans to submit an IND for HWK-206 in mid-2026 and initiate a Phase 1 trial in Q3 2026.
  • Phase 1 trials for HWK-007 and HWK-016 are currently ongoing.

The players

Whitehawk Therapeutics

A clinical-stage oncology therapeutics company applying advanced technologies to deliver improved antibody-drug conjugate (ADC) cancer treatments.

David Dornan, PhD

Chief Scientific Officer of Whitehawk Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Across our three ADC programs, we have a consistent preclinical profile characterized by potent tumor regressions, high plasma stability and favorable tolerability in non‑human primates, coupled with low systemic levels of free payload.”

— David Dornan, Chief Scientific Officer

What’s next

Whitehawk plans to submit an Investigational New Drug (IND) application for HWK‑206 in mid-2026 and initiate a Phase 1 clinical trial in Q3 2026.

The takeaway

Whitehawk's preclinical data suggest its next-generation ADC portfolio, built on its proprietary platform, has the potential to overcome limitations of first-generation ADCs and deliver a differentiated, best-in-class therapeutic index for cancer patients.